Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-255 vs Placebo Following CD19-directed CAR-T Cell Therapy in Relapsed/Refractory Large B-cell Lymphoma
NCT05664217Phase 3Terminated
- Sponsor
- Nektar Therapeutics
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of NKTR-255 in diffuse large B-cell lymphoma (DLBCL), sponsored by Nektar Therapeutics. Started Feb 2023; status: terminated.
02
Drugs
NKTR-255
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05664217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664217.